Company intelligence / Profile preview
Salubris Biotherapeutics
Gaithersburg, Maryland, United Statessalubrisbio.com ↗
- Ownership
- Private
- Development stage
- Other
01
Overview
Salubris Biotherapeutics is advancing a pipeline of novel biologic therapies, with its lead program (JK07) in Phase 2 for heart failure showing promising 6-month Phase 1b data on heart function; JK08, an IL15-CTLA4 antibody fusion for cancer, is in Phase 1b/2; JK06, a biparatopic ADC targeting 5T4 for oncology, is entering Phase 1/2 trials[4][5][6].
- Therapeutic areas
- OncologyNeurologyCardiovascular
- Modalities
- Antibody fusion proteinAntibody-drug conjugateBispecific monoclonal antibodyFusion protein
- Industry
- Biotech
02
Drug pipeline
4 assets3 more assets in the full pipeline.
03
Partnerships
MabPlex (contract development and manufacturing partner for ADC program JK06)GeneKey Biotech (China-based biologics subsidiary of parent, for cross-functional collaboration)
Beyond the preview
Go deeper on Salubris Biotherapeutics.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Follow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Explore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Trace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Compare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Explore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Connect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Salubris Biotherapeutics.